Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A by Domi, Teuta et al.
Domi et al. Skeletal Muscle  (2015) 5:30 
DOI 10.1186/s13395-015-0055-5RESEARCH Open AccessMesoangioblast delivery of miniagrin
ameliorates murine model of merosin-deficient
congenital muscular dystrophy type 1A
Teuta Domi1†, Emanuela Porrello1†, Daniele Velardo1†, Alessia Capotondo2, Alessandra Biffi2, Rossana Tonlorenzi1,
Stefano Amadio1, Alessandro Ambrosi3, Yuko Miyagoe-Suzuki4, Shin’ichi Takeda4, Markus A. Ruegg5
and Stefano Carlo Previtali1*Abstract
Background: Merosin-deficient congenital muscular dystrophy type-1A (MDC1A) is characterized by progressive
muscular dystrophy and dysmyelinating neuropathy caused by mutations of the α2 chain of laminin-211, the
predominant laminin isoform of muscles and nerves. MDC1A has no available treatment so far, although preclinical
studies showed amelioration of the disease by the overexpression of miniagrin (MAG). MAG reconnects orphan
laminin-211 receptors to other laminin isoforms available in the extracellular matrix of MDC1A mice.
Methods: Mesoangioblasts (MABs) are vessel-associated progenitors that can form the skeletal muscle and have
been shown to restore defective protein levels and motor skills in animal models of muscular dystrophies. As gene
therapy in humans still presents challenging technical issues and limitations, we engineered MABs to overexpress
MAG to treat MDC1A mouse models, thus combining cell to gene therapy.
Results: MABs synthesize and secrete only negligible amount of laminin-211 either in vitro or in vivo. MABs engineered
to deliver MAG and injected in muscles of MDC1A mice showed amelioration of muscle histology, increased expression
of laminin receptors in muscle, and attenuated deterioration of motor performances. MABs did not enter the peripheral
nerves, thus did not affect the associated peripheral neuropathy.
Conclusions: Our study demonstrates the potential efficacy of combining cell with gene therapy to treat MDC1A.
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Merosin-deficient congenital muscular dystrophy type 1A
(MDC1A; OMIM #607855) is a severe and progressive
muscle-wasting neuromuscular disease that frequently
leads to death in early childhood. The disease is inherited
as autosomal recessive and is characterized by muscular
dystrophy, dysmyelinating neuropathy, and minor brain
abnormalities [1, 2]. MDC1A is caused by mutations in
the LAMA2 gene, which encodes the α2 chain of laminin-
211 (or merosin), the major component of the basement
membrane of muscles and peripheral nerves [3].* Correspondence: previtali.stefano@hsr.it
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article, unless otherwise stated.Mutations result in loss of interaction with laminin-211
receptors expressed by striated muscle and Schwann cells,
primarily integrin α7β1, α6β1, and dystroglycan [4–6],
thus leading to progressive tissue degeneration and ul-
timately to muscular dystrophy and neuropathy [7–13].
Several mouse models for MDC1A are available: the
spontaneous mutant dy2J/dy2J (abbreviated as dy2J, this
point on) resulting in a truncated protein, which displays
a mild phenotype [14–16]; the complete null mutant
dy3K/dy3K (abbreviated as dy3K, this point on), which has a
severe phenotype [17], and the dyW/dyW mutant, a mouse
that still synthesizes a very small amount of truncated
laminin α2 chain [18].
There is currently no therapy to treat MDC1A. How-
ever, in the last years, promising therapeutic attempts
have been carried out using mouse models. Recentis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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form of agrin, miniagrin (MAG), which binds to dys-
troglycan but not integrin α7β1, ameliorates the dis-
ease in MDC1A mouse models [19–21]. In fact, MAG
acts as a linker between dystroglycan and other lam-
inin isoforms (laminin-411 and -511), which are over-
expressed in MDC1A but cannot bind efficiently to
dystroglycan [3, 19, 22, 23]. Along with transgenic
overexpression of MAG, engineered adeno-associated
viral (AAV) vector to systemically deliver MAG showed
similar efficacy to ameliorate muscular dystrophy in
MDC1A mouse model [24]. However, although these data
point the way to a promising new therapeutic approach
for MDC1A, direct gene therapy in humans still presents
challenging technical issues and limitations in terms of
safety and efficacy [25, 26].
Cell therapy has been considered a suitable and more
feasible approach for treatment of human neuromuscular
disorders, either when it has been used for tissue repla-
cement [27, 28] or as a carrier vehicle to deliver protein of
interest [29, 30]. Mesoangioblasts (MABs) are vessel-
associated progenitors [31], which can be isolated from
mesodermal tissues and expanded in vitro. MABs repopu-
late the skeletal muscles when injected into the blood
stream or directly into the muscles. MABs have been
shown to restore to a significant extent muscle struc-
ture and function in animal models of muscular dys-
trophy [32–36], and based on this preclinical evidence
on safety and efficacy, a clinical trial with allogenic MABs
transplanted in patients with Duchenne muscular dys-
trophy has been performed at the San Raffaele Scientific
Institute in Milan (EudraCT no. 2011-000176-33).
Here, we show that by combining MAB cell therapy
with MAG delivery, we ameliorated the phenotype of
MDC1A mouse models. MABs were engineered to pro-
duce mouse MAG (mMAG) and were delivered into adult
dy2J mice. Treated mice showed diffuse expression of
mMAG at the sarcolemma surface and increased expres-
sion of laminin-211 receptors. Significant amelioration of
muscle histology and reduced deterioration of motor per-
formances were observed, whereas no effects on periph-
eral neuropathy were noted. This is one of the first cell
therapy approaches to MDC1A, and our findings suggest
a novel feasible strategy to treat MDC1A with realistically
fast translation into clinical practice.
Methods
Mice
All the experiments received ethical approval and were
performed in agreement with the Ospedale San Raffaele
Institutional Animal Care and Use Committee (IACUC
authorization #487 and #664). The dy2J/dy2J (C57BL/6J
background) and NOD SCID (NOD.CB17-PrkdcSCID/J or
SCID; NOD/ShiLtSz background) mice were purchasedfrom Jackson Laboratories (Bar Harbor, USA). The dy3K/
dy3K (C57BL/6J background) mice were previously de-
scribed [17]. Both dy2J/dy2J and dy3K/dy3K mice were
maintained in the C57BL/6J background; double dy2J/
dy2J//NOD SCID mice (abbreviated as SCIDdy2J, this
point on) were in mixed background at F2/F3 generation.
For routine genotyping, we isolated genomic DNA from
tail biopsies, using DirectPCR solution (Viagen), according
to the manufacturer’s directions. Primer sequences are
available upon request.Cell cultures
Clone D16 and C57 of mouse MABs were previously
described [34, 37]. MABs and MABs carrying minia-
grin (MABs + mMAG) were maintained in culture in
Dulbecco’s modified Eagle’s medium (DMEM, high glu-
cose; Invitrogen) supplemented with 20 % of heat-
inactivated fetal bovine serum (FBS; EuroClone), 2 mM
glutamine, 1 mM sodium pyruvate, 100 IU ml−1 penicillin,
and 100 μg ml−1 streptomycin (Invitrogen) in 5 % CO2 hu-
midified atmosphere. Myogenic differentiation of MABs
was induced by plating 75 × 103 cells onto 0.1 % poly-L-ly-
sine hydrobromide, collagen (1 mg/ml)-coated dishes
(Sigma). Differentiation medium consisted of DMEM sup-
plemented with 2 % horse serum (Sigma), 2 mM glutam-
ine, 1 mM sodium pyruvate, 100 U ml−1 penicillin, and
100 μg ml−1 streptomycin (Invitrogen). Cultures were in-
cubated at 37 °C, 5 % CO2 for different periods (5–10 days)
and then processed for immunofluorescence analysis. Hu-
man MABs were obtained from healthy donors as de-
scribed in [37].Mesoangioblast treatment with 5-azacytidine and
trichostatin A
Inhibition of DNA methyl-transferase and/or histone dea-
cetylase was performed in proliferating or differentiated
murine MABs. For proliferation conditions, MABs were
plated in proliferation medium (DMEM supplemented with
15 % fetal bovine serum (Invitrogen) at 1.2 × 103 cells/cm2
density on 6-well multiwells. 5-Aza-2′deoxycytidine (AZA)
was added to 1 uM final concentration every 24 h for 3 days.
Trichostatin A (TSA) was added to 1 uM final concentra-
tion on day 3, 12–15 h before collecting cells for analysis.
For differentiation conditions, MABs were plated in prolif-
eration medium at 1.2 × 103 cells/cm2 density on collagen
(1 mg/ml) coated 6-wells multiwells (dilution 1:100). AZA
was added to 1 uM final concentration every 24 h for
5–7 days, shifting to differentiation medium (DMEM
supplemented with 2 % horse serum; Invitrogen) on
day 3. TSA was added to 1 uM final concentration on
days 5–7 (differentiation of cells should be achieved),
12–15 h before collecting cells for analysis.
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Total RNA was isolated from murine-differentiated MABs
using TriPure Isolation Reagent (Roche) according to the
manufacturer’s instructions. In brief, cells were homoge-
nized in the presence of TriPure Isolation Reagent, and
total RNA was extracted with chloroform and precipitated
with isopropanol. Two micrograms of total RNA was
reverse transcribed using a High-Capacity cDNA Re-
verse Transcription kit (Applied Biosystems). Quanti-
tative RT-PCR analyses were performed on a 7900HT
Real-Time PCR System using the 2× TaqMan PCR Mas-
termix (Applied Biosystems) according to manufacturer’s
recommendations. The primers used were TaqMan Gene
Expression Assays ID: Mm01203489_g1 for MyoD1,
Mm00446195_g1 for MyoG, and Mm99999915_g1 for
Gapdh. Levels of gene expression were determined
with the comparative cycle threshold (ΔΔCt) method.
The mRNA level of Myod1 and MyoG gene was normal-
ized to the level of Gapdh mRNA.
Each time point is the mean of three experiments.
Mesoangioblast transplantation
Thirty dy2J mice were immunosuppressed using daily injec-
tion of tacrolimus (FK506 at 2.5 mg/kg; Astellas), started
3 days before the first cell injection (42 days of age). We
then injected saline, MABs, or MABs + mMAG (ten mice
per group, see scheme in Fig. 5a) into the tibialis anterior,
gastrocnemius, and quadriceps muscles of dy2J mice, start-
ing at 45 days of age. Only before this first cell (or saline)
injection, all the dy2J mice were treated (intramuscular in-
jection) with 20 μg of cardiotoxin (CTX from Naja mos-
sambica mossambica; Sigma; 0.5 μg/μl, 40 μl vol. per
muscle), injected 24 h before MAB/saline. Prior to any pro-
cedure, mice were anesthetized by intraperitoneal injection
of avertin (2,2,2-tribromoethanol, Sigma-Aldrich) in 0.9 %
saline solution. Intramuscular delivery was performed
by the injection of approximately 1 × 106 MABs or
MABs + mMAG using a 30-gauge needle. Control mice
(dy2J not treated) were injected only with saline solution.
All dy2J mice received saline, MABs, or MABs + mMAG
(same dosage) at 55, 65, and 75 days of age (Fig. 5a) and
were analyzed for treadmill and histology at 85 days of
age. Dy3K mice were treated as described above at 18 days
of age and analyzed 7 days after MAB injection.
Histology and immunohistochemistry
Muscle samples were rapidly frozen in liquid nitrogen cooled
isopentane (Sigma). Muscle histology and hematoxylin and
eosin (H&E; Bio-Optica) staining was performed according
to standard laboratory protocol. Immunofluorescence was
performed as previously described [38] and examined with
confocal (Leica SP5, Leica Microsystems) and fluorescence
(Olympus BX51) microscopes. For cell cultures, cells
were grown on onto 0.1 % poly-L-lysine hydrobromide-coated glass coverslips, washed with PBS, and fixed with
4 % paraformaldehyde at room temperature for 10 min.
After the incubation with the primary antibody, cells or
tissue sections were washed in PBS, incubated with appro-
priate FITC- or TRITC-conjugated anti-rabbit, anti-rat or
anti-mouse antibody for 30 min at RT, washed in PBS, and
then mounted on glass slides with Vectashield Mounting
Medium (Vector Laboratories).
Sirius Red staining for collagen deposition was per-
formed as follows: muscle cryosections were treated over-
night with Bouin solution (picric acid, formaldehyde, and
5 % acetic acid), washed and then incubated for 1 h in 1 %
direct red solution and picric acid; washed in 2 % acetic
acid and then in 1:1 solution ethanol/picric acid, dehy-
drated, cleared in xylene, and coverslipped with mounting
medium.
For quantification, digitalized images were collected using
light Olympus (BX51) microscope and digital camera
(DFC300F Leica Microsystems). Muscle fiber size dis-
tribution and number of centrally located nuclei was
determined on H&E-stained tibialis anterior muscle
cross-sections by means of the QWin software (Leica
Microsystems) as described [38]. At least four random
images (×10 objective), representing the dystrophic
areas of histologic mid-belly muscle sections from five
different mice per genotype were analyzed, correspo-
nding to a minimum of 5000 muscle fibers per mouse.
Quantification of muscle fibrosis was performed by using
ImageJ software (NIH) on Sirius Red-stained cryosections,
four random images (×10 objective) representing the dys-
trophic areas of histologic mid-belly muscle sections from
five different mice per genotype. Sirius Red-stained area
was calculated as a percentage of total muscle area
analyzed.
Peripheral nerve semithin sections were performed as
described [39], stained with toluidine blue, and exam-
ined by light (Olympus BX51) and electron (CEM 902;
Carl Zeiss) microscopy.
Western blot
Cells were homogenized in protein extraction buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA,
1 % triton supplemented with proteases inhibitors). Pro-
tein concentrations were determined by Bradford pro-
tein assay (Bio-Rad). Twenty micrograms of proteins
were loaded and separated on a 10 % SDS-PAGE and
immunoblotted for the detection of mMAB protein, ex-
cept for the detection of laminin α2 in the experiments
with trichostatin and AZA, in which we loaded 150 μg
of proteins per lane to be able to detect a minimal
amount of laminin α2. Muscles were powdered in liquid
nitrogen using a mortar and a pestle. Protein extraction
was completed in ice-cold lysis buffer containing: 75 mM
Tris-HCl pH 6.8, 1 % SDS supplemented with proteases
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ase inhibitors (PhosSTOP, Roche). Then, the samples were
sonicated and centrifuged for 5 min at 13,000 rpm. Super-
natants were collected and protein concentrations were
quantified using the BCA protein assay (Pierce). Twenty
micrograms of proteins of total homogenates were loaded
and separated on 8–12 % SDS poliacrylamide gels at 80 V
for 3 h. Proteins were then transferred to nitrocellulose
membranes (Bio-Rad) at 35 V O/N at 4 °C, and membranes
were stained with Ponceau (Sigma) to ensure equal protein
loading. Membranes were saturated with 5 % milk in 0.1 %
Tween-20 (Sigma) PBS for 1 h at RT and hybridized for 2 h
at RT with the following primary antibody. Detection was
carried out by incubation with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG (Santa Cruz
Biotechnology) for 1 h at RT. The proteins were visualized
by ECL immunoblotting detection system (Amersham).
Densitometric analyses were performed by using the Scion
Image software. Averages of densitometric measurements
of independent experiments, normalized by the endoge-
nous β-actin or β-tubulin values, were compared by
Student's t test. The results shown in the figures are repre-
sentative of three separate experiments. Data are expressed
as means ± SEM.
Antibodies
Antibodies used for immunohistochemistry and/or Western
blot analysis included (p = polyclonal, m = monoclo-
nal, Ch = chicken, Ms = mouse, Rb = rabbit, Gt = goat,
Rt = rat): α-actin (mMs Sigma); calnexin (pRb; Sigma
C4731); β-dystroglycan (mMs, 8D5, Novocastra); α-
dystroglycan (mMs, nIIH6C4, Millipore) and α-dystroglycan
(mMs, VIA4-1, Millipore); integrin α5 (pRb, AB1949, Milli-
pore); integrin a6 (mRt, GoH3 from A. Sonnenberg);
integrin α7 (pRb, from Dr. U. Mayer); β1 integrin (pRb;
Millipore); laminin α1 (mRt, AL-1, Millipore); laminin
α2 (mMs; Alexis 4H8-2) and laminin α2 (mMs; 1:200,
gift from H. Hori); laminin α4 (pRb, H-194, Santa Cruz);
laminin α5 (pRb, 405, from Dr. Sorokin); laminin γ1 (mRt,
MAB1914, Millipore); laminin HSA (pRb, L9393, Sigma);
myc tag (mMs; Cell Signaling); myosin heavy chain (mMs,
Hybridoma Bank); neurofilament M (pCh; 1:1000, Cov-
ance PKC-593P); and β-tubulin (mMs; TUB2.1, Sigma).
TUNEL assay
Terminal deoxynucleotidyl transferase dUTP nick end la-
beling (TUNEL) assay was performed as described [39],
using the fluorometric TUNEL System G3250 Kit (Pro-
mega). Briefly, cryosections (10 μm thick) of quadriceps
muscles were fixed in 4 % paraformaldehyde, perme-
abilized in 0.1 % triton, treated with DNase solution, and
finally DNA strand breaks labeled with fluorescein-12-
dUTP by deoxynucleotidyl transferase (TdT)-reaction mix
for 60 min before the stop reaction. Nuclei were identifiedby DAPI and muscle fibers by anti-total-laminin antibody.
For quantification, TUNEL/DAPI double positive nuclei
associated with single muscle fiber were counted and
expressed as the percentage of total number of positive fi-
bers; we counted at least 1600 fibers per mouse, three mice
per genotype.
Cell transfection with lentiviral vectors
Lentiviral production and transfection was performed as
previously described [29]. Briefly, 3.2 kb of mMAG con-
struct (including a myc tag) was sequenced and subcloned
downstream of the uni-directional hPGK promoter of the
pCCLSIN.PPT.hPGK.wPRE lentiviral vector (LV). Con-
centrated mMAG LV stocks pseudotyped with the VSV.G
envelope were produced by transient co-transfection of
four plasmids in 293T cells and titreted on HeLa cells.
MABs were transduced at multiplicity of infection (MOI)
of 100 with mMAG LV or control vector. Ten days after
transduction, MABs were collected and proteins secreted
in cell culture medium were precipitated to evaluate the
expression of mMAG. The presence of mMAG was tested
by Western blot using anti-myc tag antibody.
Treadmill exercise
Functional muscle activity was measured by using the ex-
haustion treadmill to assess resistance to fatigue. For the
pretreatment exercise test, 30 45-day-old dy2J mice were
tested for functional performance with the treadmill test
(Columbus Instruments, Columbus, OH, USA). MAB-
treated and not-treated mice were retested for functional
recovery at 85 days (Fig. 5a). For the exercise test, mice
were put into treadmill at 3 m/min, then the speed was
increased 1 m/min every 2 min until exhaustion. Final
value is the mean (±SEM) of three different exercises per
mouse. Mice were adapted to the procedure (10 min every
other day; 3 m/min) for 1 week before beginning the exer-
cise training protocol. The examiner was blind as respect
to the scheme of treatment. Deterioration was expressed
in percentage and measured as: B-A/A × 100; B = average
time on treadmill post-treatment, A = average time on
treadmill before treatment.
Neurophysiology
Neurophysiology was performed as described [38]. The dy2J
mice were analyzed before (45 days of age) and after (85 days
of age) MAB treatment (see scheme in Fig. 5a). Mice were
anesthetized with tribromoethanole (Avertine; Sigma) and
placed under a heating lamp to avoid hypothermia. Sciatic
nerve conduction velocities (NCV) were obtained by stimu-
lating the nerve with steel monopolar needle electrodes. A
pair of stimulating electrodes was inserted subcutaneously
near the nerve at the ankle, and then they were moved to
the sciatic notch to obtain two distinct sites of stimulation,
proximal and distal along the nerve, in order to obtain the
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sponse to the electrical nerve stimulation (compound motor
action potentials (cMAP)) was recorded with a pair of needle
electrodes; the active electrode was inserted in muscles
in the middle of the paw, while the reference was
placed in the skin between the first and second digit.
The cMAP peak-to-peak amplitude was considered for
analysis. The examiner was blind as respect to the
scheme of treatment.Statistical analysis
Values were expressed as means ± SEM. Significance of
the differences was assessed between means by two-
tailed unpaired Student’s t test or ANOVA with Tukey’s
post hoc test (GraphPad Prism software version 5). We
investigated the differences between the distributions by
means of the Mann-Whitney test and verified for sto-
chastic dominance. To take into account of test multipli-
city, p values were adjusted for false discovery rate [40].Fig. 1 MABs do not synthesize laminin α2 neither in vitro nor in vivo. a Wester
undifferentiated MABs, and medium from differentiated and undifferentiated M
type muscle homogenate, whereas a polyclonal antibody recognizing laminin c
medium from differentiated and undifferentiated MABs. Calnexin is shown as lo
lane is loaded with 40 μg of protein. b Cultures of MABs differentiated in myotu
antibody, show positive staining for laminin chains γ1. DAPI staining identifies n
(MyHC positive) do not show staining with anti-laminin α2 chain antibody. DAPA probability of less than 5 % (p < 0.05) was considered
to be statistically significant.
Results
Mesoangioblasts do not express laminin-211 but laminin-411
and laminin-511
Previous studies showed that MABs either directly trans-
planted in the skeletal muscle or injected into the blood
stream can engraft dystrophic muscles and restore the
expression of muscular proteins of different types of
dystrophic mice [32–36, 41]. In order to evaluate if MABs
may be useful to ameliorate MDC1A, we first investigated
if MABs can synthesize and express laminin-211. MABs
(cell line C57 and D16) were grown undifferentiated or
were differentiated to myotubes, and the expression of
laminin α2, β1, and γ1 was investigated by Western blot
analysis and immunohistochemistry. We did not detect any
laminin α2 chain either in cell homogenate or medium of
both undifferentiated and differentiated MABs (Fig. 1a).
Conversely, we detected both laminin chains β1 and γ1n blot analysis of mouse wild type (C57Bl6) muscle, differentiated and
ABs. Anti-laminin α2 chain antibody detects a specific band only in wild
hain β1 and γ1 detects specific bands in all the homogenates, including
ading control (accordingly, it is absent when only medium is loaded). Each
bes, as depicted by positive staining with anti myosin heavy chain (MyHC)
uclei. Scale bar = 30 μm. c Cultures of MABs differentiated in myotubes
I staining identifies nuclei. Scale bar = 30 μm
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MABs, either undifferentiated or differentiated to myotubes
(MyHC positive), stained positive with polyclonal antibody
recognizing laminin chains β1 and γ1 but not with specific
monoclonal antibody recognizing laminin α2 (Fig. 1b, c).
We then evaluated if MABs can synthesize other lam-
inin isoforms expressed in the muscle and nerve and
observed in MDC1A mutants [3, 4, 19, 23]: we detected
by immunohistochemistry laminin chains α4 and α5
but not α1 (Fig. 2a–c). Thus, MABs can assemble
laminin-411 and -511 but not -211 and -111.
To evaluate whether reduced capacity of MABs to
synthesize laminin α2 was due to epigenetic events, we
tested if histone deacetylase and/or methyl-transferase
inhibitors could modify the expression of laminin α2 in
murine MABs. We treated undifferentiated and differ-
entiated C57 murine MABs with 5-aza-2′deoxycytidine
(AZA; to inhibit histone deacetylase), trichostatin
(TSA; to inhibit methyl-transferase), or both AZA +
TSA. To detect minimal amount of laminin α2, we
overloaded samples (150 μg per lane) and overexposed
the membrane stained with anti α2 antibody. In all of
these conditions, neither undifferentiated (not shown)
nor differentiated MABs showed significant differencesFig. 2 MABs can synthesize laminin chains α4 and α5 but not α1. a Cultures of
with anti-laminin α1 chain antibody. DAPI staining identifies nuclei. a′ is the sam
MABs differentiated in myotubes show positive staining for laminin α4. DAPI sta
in myotubes show positive staining for laminin α5. DAPI staining identifies nuclein laminin α2 expression (Fig. 3a, b). As expected, as
positive control for treatment, MyoG and MyoD ex-
pression was increased in MABs treated with AZA and
decreased in those treated with TSA, as reported for
C2C12 cells (Fig. 3c, d) [42–44].
Finally, we tested whether impaired synthesis of lam-
inin α2 was restricted to mouse MABs. Human MABs
were derived from two healthy individuals and expanded
in culture. Again, Western blot analysis revealed only
minimal (if any) laminin α2 in human MABs (Fig. 3e).
Overall results show that MABs do not synthesize
(or they do in minimal amount) laminin-211, suggest-
ing that they may not be sufficient to rescue MDC1A
disease.
Engineered mesoangioblasts can synthesize and secrete
miniagrin in muscles of MDC1A mice
As MABs cannot synthesize laminin-211, their potential
efficacy in the treatment of MDC1A would be limited.
Conversely, the overexpression of miniagrin gene was
shown to ameliorate the muscular dystrophy in MDC1A
mutants. We thus evaluated if the combination of MABs as
carrier cells to deliver miniagrin protein into degenerating
tissues may ameliorate the phenotype of MDC1A mouseMABs differentiated in myotubes (MyHC positive) do not show staining
e image as in (a), without MyHC staining. Scale bar = 30 μm. b Cultures of
ining identifies nuclei. Scale bar = 30 μm. c Cultures of MABs differentiated
i. Scale bar = 30 μm
Fig. 3 Human MABs and mouse MABs treated with deacetylating and demethylating substrates express very little amount of laminin α2 chain. a Western
blot analysis of homogenates from differentiated mouse MABs (150 μg of protein loaded per lane) untreated (CTR) or treated with 5-aza-2′deoxycytidine
(AZA), AZA and trichostatin A (AZA + TSA), or trichostatin A (TSA) for 3 days. Deacetylation (AZA) and/or demetylation (TSA) do not modify the expression
of laminin chain a2, β1, and γ1. Calnexin (Cnx) is shown as reference for protein loading. b Quantification of densitometric results of the above the Western
blot analysis as ratio between laminin chain α2 and calnexin, representing the mean of three determinations (±SEM). c–d Quantitative PCR analysis for
MyoD (c) and MyoG (d) of differentiated MABs untreated or treated with AZA, AZA + TSA, or TSA; as expected MyoG was significantly increased by AZA
and decreased by TSA treatment. eWestern blot analysis of homogenates from human fibroblasts, human MABs, and human myoblasts. One hundred
micrograms of protein were loaded per lane. Anti-laminin α2 chain antibody detects positive band in fibroblasts and myoblasts, whereas very little (if any)
positive staining is present in human MABs. All three homogenates stained positive for laminin chain β1 and γ1
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[34]) was infected with lentiviral vectors carrying the cDNA
of mouse miniagrin [20]. By immunohistochemistry, 95 %
of infected MABs showed positive staining for miniagrin,
recognized by anti-myc antibody (Fig. 4a (a)). We then
evaluated whether MABs carrying miniagrin (MABs +
mMAG) not only synthesize but also secrete miniagrin.
MABs + mMAG, and non-infected MABs as control,were grown in petri dishes for 3 days. Medium and cell
homogenate was analyzed by Western blotting to investi-
gate the presence of miniagrin. As expected, anti-myc
antibody recognized miniagrin in the cell homogenate
of MABs + mMAG (Fig. 4a (b)). Similarly, miniagrin
was detected in the medium obtained from MABs +
mMAG. Lack of β-tubulin confirmed that no (necrotic)
cells were present in the medium (Fig. 4a (b)). The
Fig. 4 MABs + mMAG can express and synthesize miniagrin and when injected in dy2J colonize the skeletal muscles but not the peripheral nerves. a C57
MABs transduced with miniagrin gene carrying myc tag show diffuse positivity when stained with anti-myc antibody (a DAPI staining identifies nuclei); scale
bar = 30 μm. b Western blot analysis with anti-myc antibody, recognizing mMAG, of cell homogenate and medium from cultures of C57 MABs and C57 MABs
transduced with miniagrin gene (MABs + mMAG). Anti-myc recognizes a band only in the homogenate and medium of transduced MABs. β-Tubulin is shown
as loading control (accordingly, staining is not present in medium). Each lane is loaded with 25 μg of proteins. b Cryosection of the tibialis anterior muscle
from dy2J mouse treated for 10 days with MABs + mMAG. Double staining with anti-laminin γ1 (a depicting myofibers, in red) and anti-myc antibody (b
recognizing mMAG, in green) shows diffuse expression of miniagrin around myofibers; scale bar = 50 μm. c Same muscle showing myc-positive fibers with
centrally located nuclei (identified by DAPI, in blue), suggesting regenerating fibers; scale bar = 25 μm. c Cryosection of the tibialis anterior muscle from dy2J
mouse treated for 10 days with MABs + mMAG. Double staining with anti-laminin γ1 (a depicting myofibers, in red) and anti-myc antibody (b recognizing
mMAG, in green) shows that myc positivity is not diffuse to the entire muscle but limited to the area of injection (asterisk). Scale bar = 50 μm. d Cryosection
of the tibialis anterior muscle from dy3K mouse 10 days after i.m. injection of MABs carrying a myc tag. Staining with anti-myc antibody recognizes an area
where MABs secreted mMAG a, whereas staining with anti-laminin α2 antibody does not show positive signal (b DAPI staining identifies
nuclei). Scale bar = 25 μm. e Cryosection of intramuscular nerves of the tibialis anterior muscle from dy2J mouse treated for 10 days with
MABs + mMAG. Double staining with neurofilaments (NF) recognizing axons a and anti-myc antibody b recognizing mMAG. Myc staining
is restricted to the perineurium and blood vessels, whereas only scarce and scattered positivity is present in the endoneurium. DAPI staining identifies
nuclei. Scale bar = 20 μm
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as negative control did not show any positive staining
for miniagrin (Fig. 4a (b)). These data show that MABs
engineered with the miniagrin gene can synthesize and
secrete the miniagrin protein.We then evaluated if MABs + mMAG (clone C57) can
synthesize and deliver mMAG in the skeletal muscles and
peripheral nerves when injected into MDC1A mouse
model. To avoid cell rejection, as the MAB C57 clone was
allogeneic to mouse mutants, we treated all mice with
Domi et al. Skeletal Muscle  (2015) 5:30 Page 9 of 17tacrolimus (FK506), 25 mg/kg/day, starting 3 days before
the first cell injection. One million cells (MABs + mMAG,
carrying myc tag) were injected intramuscularly into the
tibialis anterior and gastrocnemius muscle of three 45-day-
old dy2J mice (carrying laminin a2 mutation) and three 18-
day-old dy3K mice (completely devoid of laminin α2). Mice
were euthanized 10 days after MABs injection, and mus-
cles were stained with anti-myc and anti-laminin anti-
bodies. In both strains (dy2J and dy3K), we observed diffuse
myc staining around muscle fibers (identified by anti-
laminin γ1) in the area of injection (Fig. 4b and data not
shown). In many cases, myc-positive fibers showed cen-
trally located nuclei or were NCAM positive, suggesting
that they were regenerating fibers (Fig. 4b (c) and not
shown). The myc-positive staining was limited to the area
of injection, in fact, the rest of the muscle appeared myc-
negative (Fig. 4c), and we did not observe myc-positive
staining in other muscles within the same leg or in the
contralateral leg (data not shown). Interestingly, although
we observed myc staining in the injected muscles of dy3K
mice, indicating that MABs are present and can synthesize
and secrete myc-tagged miniagrin, we did not observe any
staining for laminin α2 (Fig. 4d), suggesting that even
in vivo MABs cannot synthesize and secrete laminin-211.
Finally, we observed that sciatic nerve branches showed
intense myc-positive staining only in the perineurium or
around large perineurial blood vessels, whereas only rare
myc-positive staining was detected in the endoneurium,
suggesting that MABs or delivered miniagrin do not enter
the peripheral nerves (Fig. 4e).
Overall, these results show that MABs can deliver min-
iagrin in vivo, which localizes around muscle fibers in
strict correlation with laminins and laminin receptors.
dy2J Mice treated with MABs + mMAG show better motor
performances and ameliorated muscle histology.
We then evaluated whether i.m. injection of MABs and
miniagrin delivery may ameliorate muscle histology and
motor performances of MDC1A mutants. As this would
represent a proof of principle study, and due to lifespan
limitation of the dy3K model, we decided to use adult
dy2J mice and to inject only few large muscles of the
posterior limbs.
Thirty 45-day-old dy2J mice were divided into three
groups: group 1, ten mice were treated with normal
saline solution as controls; group 2, ten mice were
treated with MABs + mMAG; and group 3, ten mice
were treated with MABs (without mMAG). Every mouse
received 1.0 × 106 cells by i.m. injection in the tibialis
anterior, gastrocnemius, and quadriceps muscle, bilat-
erally, every 10 days for four times as depicted in Fig. 5a.
Motor performances of all mice were evaluated with
treadmill test before the first injection (45-day-old) and
10 days after the last injection (85-day-old), and thepercentage of deterioration measured (as described in
methods). Motor performances of dy2J mice treated with
MABs + mMAG deteriorated significantly less than the
dy2J mice treated with saline (Fig. 5b; ANOVA 2 tails
p = 0.01, n = 10). Conversely, we did not observe signifi-
cant differences between dy2J treated with MABs alone (no
miniagrin) as compared to those treated with saline (Fig. 5b;
p = 0.63, n = 10).
We then analyzed muscle histology. Fibrosis is a typ-
ical feature of dystrophic mice. We evaluated fibrosis by
comparing mice in the three groups. Endomysial con-
nective tissue, identified by Sirius Red staining, was mea-
sured and expressed as percentage of the evaluated
muscle area. We observed a significant decrease of the
fibrotic area in dy2J mice treated with MABs + mMAG
as compared to dy2J-untreated mice (Fig. 5c; ANOVA 2
tails p = 0.005, n = 5 mice) or mice treated only with
MABs (ANOVA 2 tails p = 0.0004; n = 5 mice).
Mice treated with MABs + mMAG also showed amelior-
ation of muscle histology. In fact, dy2J treated with MABs +
mMAG (group 2) showed myofibers with larger diameter
as compared to dy2J mice (group 1, treated with saline) and
those treated with MABs alone (group 3). We observed in
the tibialis anterior muscle a significant shift to the right of
the histogram when fibers were plotted against diameters
(Fig. 5d), as estimated by comparing differences between
data distribution (test for stochastic dominance: p < 0.001);
similar significant difference was also present between mice
treated with MABs + mMAG as compared to those treated
with MABs alone (test for stochastic dominance: p < 0.001).
Accordingly, in the gastrocnemius, the number of fibers of
small diameter (10–30 μm) was slightly reduced although
not significantly in dy2J mice treated with MABs + mMAG
(group 3; 168 ± 50 fibers per 0.1 mm2) as compared to dy2J
mice treated with saline (group 1; 236 ± 45 fibers per
0.1 mm2; p = not significant, n = 4), whereas the number of
fibers of larger diameter (40–60 μm) was significantly in-
creased dy2J mice treated with MABs + mMAG (80 ± 7
fibers per 0.1 mm2) as compared to dy2J mice treated with
saline (27 ± 9 fibers per 0.1 mm2; ANOVA 2 tails, p = 0.02;
n = 4).
When we evaluated the number of fibers with centrally
located nuclei, as representative of regenerating fibers to
counteract degeneration, we did not observe significant
differences between treated and untreated mice: the
number of fibers with central nuclei was slightly
decreased in dy2J mice treated with MABs + mMAG
(31.3 ± 4.2 %) when compared to dy2J mice treated with
saline (36.8 ± 3.5 %, ANOVA, p = not significant, n = 5
per group) or treated with MABs (43.5 ± 3.6 %; ANOVA,
p = not significant, n = 5 per group).
Finally, as apoptosis may contribute to the disease pro-
gression of MDC1A [45–47], we evaluated the number
of apoptotic muscle fibers by TUNEL labeling assay in
Fig. 5 (See legend on next page.)
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Fig. 5 dy2J Mice treated with MABs + mMAG show improved locomotion. a Schematic representation of cell treatment, functional, and histological
analyses. b Treadmill analysis in ten dy2J mice untreated (saline solution, blue, group 1), ten treated with MABs + mMAG (green, group 2), and ten treated
with MABs alone (red, group 3) Average times (±SEM) measured on the treadmill before and after treatment are shown on the left. On the right, the
percentage of deterioration between the two measurements is depicted. dy2J Mice treated with MABs + mMAG deteriorate significantly less than
untreated dy2J mice (**p< 0.01; n= 10; ANOVA). dy2J Mice treated with MABs alone behave similar to controls. c Fibrosis revealed by Sirius red staining of
the tibialis anterior muscle in dy2J mice untreated (saline solution, blue), treated with MABs + mMAG (green), and treated with MABs alone (red); on the
right, representative staining of the three groups as compared to normal wild type mice. The area of fibrosis is significantly reduced in dy2J mice treated
with MABs + mMAG as compared to dy2J mice treated with saline or MABs alone. d Morphometric analysis of the tibialis anterior muscle from dy2J mice
untreated (saline, blue), treated with MABs + mMAG (green), or with MABs alone (red). The histogram shows that the fiber size distribution of dy2J mice
treated with MABs + mMAG is shifted to the right as compared to mice untreated or treated with MABs alone, indicating a higher percentage of fibers
with larger diameter. Below, the representative H&E staining of muscle histology from the tibialis anterior of the three groups of dy2J mice. Muscle atrophy
and endomysial connective tissue is prevalent in untreated muscle and in muscle treated with MABs alone. Reduced muscle fiber size variability and
connective tissue is evident in muscle treated with MABs + mMAG. Scale bar = 50 μm
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nificant differences of apoptotic cells in dy2J mice treated
with MABs (1.06 ± 0.19 %) versus MABs + mMAG
(1.44 ± 0.36 %) or versus untreated dy2J mice (1.26 ±
0.23 %;) as shown in Additional file 1: Figure S1.
MDC1A mice treated with MABs + mMAG show restored
levels of laminin-211 receptors
As laminin-411 and 511 are described upregulated in
muscles of Lama2 mice [3, 19, 22, 23], and we further
observed that MABs can synthesize laminin chain α4
and α5, we evaluated the expression of these two lam-
inin isoforms in MABs treated and untreated dy2J mice.
As expected, dy2J mice showed increased expression of
both laminin chain α4 and α5 but we did not observe
further differences after treatment with MABs (either
MABs alone or MABs + mMAG) as shown in Additional
file 2: Figure S2. Interestingly, staining for laminin chain
γ1 was changed in dy2J mice as compared to normal con-
trols, as at similar level of detection it was reduced and
discontinuous in dy2J mice, with a pattern similar to lam-
inin α5 as shown in Additional file 2: Figure S2C. Treat-
ment with MABs (either alone or MABs + mMAG) did
not modify the staining as shown in Additional file 2:
Figure S2C. This last data would be consistent with the
change of the γ1 chain from the laminin-211 heterotrimer
to the 411/511 heterotrimer in dy2J mice.
It was previously shown that constitutive overexpression
of miniagrin in transgenic mice leads to increased levels of
laminin receptors [19, 20]. As a further readout of efficacy
of our treatment, we thus evaluated if this was also
present in dy2J mice treated with MABs + mMAG. First,
we investigated the expression of integrin β1, which forms
the laminin receptors α6β1 and α7β1. With both immu-
nohistochemistry and Western blotting, we observed that
the reduced expression of β1 integrin in muscles of dy2J
mice was significantly restored after MAB treatment
(either MABs alone or MABs + mMAG; Fig. 6a, b). We
observed that also integrin α7 was reduced in dy2J mice
and restored after MAB treatment (with similar effectbetween MABs and MABs + mMAG; Fig. 6c, d). Integrin
α6 was not detectable in control muscle (except for blood
vessels and intramuscular nerves), whereas faint and dot-
ted staining was observed in some muscle fiber of dy2J
mice as shown in Additional file 3: Figure S3. In dy2J mice
treated with MABs (either MABs alone or MABs +
mMAG), this dotted α6 expression was more evident in
the muscle fibers. As integrin α5 is another β1 partner,
generating a fibronectin receptor with a relevant role in
muscle function, and the balance between laminin and
fibronectin receptors is important for muscle integrity
[48], we evaluated also α5 expression in dy2J-treated mice.
The expression of α5 integrin was significantly increased
in dy2J mice but not modified after treatment with MABs
(either MABs alone or MABs + mMAG; Fig. 6e).
The other main laminin-211 receptor in the skeletal
muscle is the dystroglycan complex, which is formed by
α-(extracellular) and β-(transmembrane) subunits [6]. dy2J
Mice showed significant reduction of β-dystroglycan,
which expression was significantly rescued at normal level
after treatment with MABs + mMAG (Fig. 7a, b). Expres-
sion of α-dystroglycan was increased in dy2J mice and not
changed after MABs treatment (Fig. 7c, d).MABs + mMAG treatment ameliorates the clinical phenotype
also in SCIDdy2J mice
As a complementary study of the efficacy of MABs + mMAG
treatment for MDC1A mouse model, we generated dy2J mice
in SCID background (SCIDdy2J). The aim of this experiment
was to evaluate the efficacy of MAB therapy in the absence of
immunoresponse and immune-suppressive therapy. Mice
were divided in two groups: group 1 included ten SCIDdy2J
mice treated with saline and group 2 included ten SCIDdy2J
mice treated with MABs + mMAG. Cell dosage, time points
of treatment, and age of treated mice were the same as
described above and summarized in Fig. 5a. Motor per-
formances of all mice were evaluated with treadmill
just before the first injection (45-day-old), and 10 days
after the last injection (85-day-old). As expected, also
Fig. 6 (See legend on next page.)
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Fig. 6 Miniagrin treatment restores expression of β1 integrin receptors. a Cryosections of the tibialis anterior muscle from dy2J mice untreated (saline
solution) or treated with MABs + mMAG double stained with anti-myc (recognizing mMAG) and anti-β1 integrin antibody. The immunofluorescence shows
that myc staining is present only in treated muscle. Staining for β1 integrin is more intense and diffuse in treated muscle. Images are acquired by confocal
microscope with the same z-stack and laser intensity. DAPI staining identifies nuclei. b Western blot analysis of the tibialis anterior muscle from dy2J mice
untreated or treated with MABs + mMAG or MABs alone and stained with anti β1 integrin, and β-actin as loading control. Quantification of Western blot
analysis is reported as an average of three independent experiments and represented as the ratios β1 integrin/actin, assigning wild type as 1. A significant
decrease of β1 integrin (n= 3) is present in muscle of dy2J mice as compare to wild type control; the amount of β1 integrin is significantly increased after
treatment with MABs + mMAG. c Cryosections of wild type (Wt), dy2J untreated (saline), dy2J treated with MABs, and dy2J treated with MABs + mMAG
stained with anti α7 integrin antibody and DAPI. Staining for α7 integrin was reduced in dy2J mice as compared to Wt and moderately increased in dy2J
mice treated with MABs + mMAG. dWestern blot analysis confirmed the decrease of α7 integrin in dy2J, whereas it was more similar to Wt in dy2J mice
treated with MABs or MABs + mMAG; differences were not significant. e Western blot analysis of α5 integrin showed a significant increase in all the dy2J
mice (treated or not treated) as compared to Wt controls. Scale bar = 50 μm in (a) and 100 μm in (c). Student t test; *p< 0.05; **p< 0.01; error bars
indicate SEM
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significant reduction in deterioration of treadmill per-
formances (−29 ± 4 %) as compared to non-treated
SCIDdy2J mice (−49 ± 9 %; Student’s t test, two tails, p= 0.05,
n= 10), despite extreme variability in genetic background
(F3/F4 generation).
Mesoangioblast treatment did not ameliorate the
peripheral neuropathy of MDC1A
Loss of laminin-211 is responsible for dysmyelinating
neuropathy in human MDC1A and animal models [17, 18,
49, 50]. Although we did not observe mMAG expression
in the endoneurium but it was limited to the perineurium
(Fig. 3d), we evaluated whether this was anyway sufficient
to modify peripheral neuropathy. Five mice in group 1
(dy2J mice treated with saline solution) and group 2 (dy2J
mice treated with MABs + mMAG) also underwent neuro-
physiological analysis at 45-day-old (before treatment) and
85-day-old (after treatment) to evaluate the effect on the
peripheral neuropathy. Neurophysiology of dy2J mice did
not show significant differences before and after treatment
with MABs + mMAG or saline. Before treatment: group 1
showed cMAP 3.95 ± 0.7 mV and NCV 33 ± 3.5 m/s,
whereas group 2 showed cMAP 3.90 ± 0.6 mV and NCV of
32 ± 4 m/s. After treatment: group 1 showed cMAP 3.2 ±
0.7 mV and NCV of 39 ± 2 m/s, whereas group 2 (MABs +
mMAG treated) showed cMAP 3.2 ± 0.5 mV and NCV of
38 ± 1.5 m/s (Student’s t test, p = not significant). Accord-
ingly, the analysis of semithin sections of the sciatic nerves
did not show differences between the two groups, as
shown in Additional file 4: Figure S4.
Overall, these data show that mMAG delivered by MABs
injected into the skeletal muscles does not enter signifi-
cantly in the peripheral nerves, and this therapy does not
interfere with the progression of the peripheral neuropathy
in MDC1A mutants.
Discussion
We propose to associate cell (MABs) and gene (mMAG)
therapy as a strategy to treat MDC1A. Results of ourproof of principle study are consistent with an amelior-
ation of morphological, molecular, and motor aspects of
MDC1A-treated mice. No effect was observed on the
associated peripheral neuropathy.
Although previous studies showed that MAB cell
therapy is sufficient to treat recessive muscular dystrophies
in preclinical models [32–36, 41], this was not considered
a successful strategy in MDC1A as we observed that MABs
synthesize and secrete only little (negligible) amount of
laminin α2, which is the missing protein in MDC1A. Lack
of laminin α2 synthesis was not restricted to mouse spe-
cies, as we observed similar result with human MABs. It
was even independent of epigenetic events, as neither
inhibition of histone deacetylation nor of DNA methyla-
tion induced murine MABs to synthesize more laminin
α2. Although this seems contradictory with the fact that
MABs differentiate into myocytes, which normally pro-
duce laminin α2, and that once differentiation is triggered
it will automatically lead to the full expression of the gene
repertoire, this is not necessarily true. It is well known that
myoblast differentiation in vitro will not give rise to the
expression of adult isoforms of sarcomeric proteins [51].
Nonetheless, previous in vivo studies showed that bone
marrow-derived stem cells differentiated into myocytes
could not synthesize δ-sarcoglycan [52].
Thus, we decided to use MABs as carrier cells to deliver
in the skeletal muscle an exogenous protein, miniagrin,
which is able to link laminin-211 receptors with other lam-
inin isoforms expressed (or even overexpressed) in the
extracellular matrix of MDC1A dystrophic mice [53]. Inter-
estingly, we showed that MABs + mMAG could profusely
synthesize these other laminin isoforms, thus increasing the
potential efficacy of this strategy. As expected, we observed
diffuse staining for mMAG (recognized by anti-myc tag
antibody) in the injected area of the skeletal muscles, which
associated with signs of regeneration (centrally located
nuclei and NCAM staining) when detected few days after
injection, and amelioration of morphological (reduction of
endomysial connective tissue and increased proportion of
fibers with large diameter, suggesting muscle reconstitution
Fig. 7 Miniagrin treatment restores expression of dystroglycan receptor in muscles. a Cryosections of the tibialis anterior muscle from dy2J mice
untreated (saline) or treated with MABs + mMAG double stained with anti-myc (recognizing mMAG) and anti β-dystroglycan integrin antibody.
The immunofluorescence shows that myc staining is present only in treated muscle. Staining for β-dystroglycan is more intense and diffuse in
treated muscle. Images are acquired by confocal microscope with the same z-stack and laser intensity. DAPI staining identifies nuclei. b Western
blot analysis of tibialis anterior muscle from dy2J mice untreated, or treated with MABs+mMAG or MABs alone, and and wild type (Wt) controls,
stained with anti β-dystroglycan, and β-tubulin as loading control. Quantification of western blot analysis is reported as an average of 3 independent
experiments and represented as the ratios β1 integrin/actin, assigning Wt as 1. A significant decrease of β-dystroglycan (n = 3) is present in muscle of
dy2J mice as compared to Wt control; the amount of β-dystroglycan is significantly increased after treatment with MABs+mMAG (n = 3). c Cryosections
of wild type (Wt), dy2J untreated (saline), dy2J treated with MABs, and dy2J treated with MABs + mMAG stained with anti α-dystroglycan antibody and
DAPI. Staining for α-dystroglycan was increased in dy2J mice as compared to Wt and more similar to Wt control in dy2J mice treated with MABs or
MABs + mMAG. Western blot analysis confirmed the significant increase of α-dystroglycan in dy2J, as compared to Wt mice; dy2J mice treated with
MABs or MABs + mMAG did not show further changes. d Western blot analysis of tibialis anterior muscle from dy2J mice untreated, or treated with
MABs+mMAG or MABs alone, and Wt controls, stained with anti α-dystroglycan, and β-tubulin as loading control. Quantification of western blot
analysis is reported as an average of 3 independent experiments and represented as the ratios β1 integrin/actin, assigning Wt as 1. A significant
increase of α-dystroglycan (n = 3) is present in muscle of dy2J mice as compared to Wt control; similar levels are also observed in dy2J mice treated
with MABs (either alone or with mMAG; n = 3). Scale bar = 50 μm in (a) and 100 μm in (c). Student t test; *p < 0.05; **p < 0.01; error bars indicate SEM
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levels of laminin-211 receptors) features when investigated
at the end of the preclinical trial. Interestingly, and consist-
ently with previous reports [19–21], it seems that both dys-
troglycan and α7β1 integrin are the two laminin receptorsrescued by MABs + mMAG treatment, as instead α6(β1),
which forms the other main integrin-laminin receptor in
the muscle [54], was not significantly upregulated. More-
over, α- and β-dystroglycan were differently regulated in
dy2J mice, but this is not new as observed also in other
Domi et al. Skeletal Muscle  (2015) 5:30 Page 15 of 17Lama2 strains [19, 21], possibly due to different regulatory
mechanisms for the two subunits when the ligand is absent
(as in dy3K or dyW) or not functioning (as in dy2J mice).
We did not investigate the extent of MABs (and MABs
+ mMAG) engraftment in the injected skeletal muscles
and that of MABs integration in regenerating fibers, as
(1) it was diffusely proven and shown in previous pub-
lished studies [32–36, 41, 55]: MABs can fuse with
regenerating myotubes and restore missing proteins in
loss-of-function myopathies; (2) this was not the scope
of our study, as our goal was to demonstrate that injected
MABs can secrete MAG in the skeletal muscles (recog-
nized by the myc tag). Moreover, we had no useful marker
to differentiate donor from endogenous nuclei in myo-
tubes of injected MDC1A muscles. However, we may
speculate that a consistent number of MABs + mMAG
have been integrated into the host MDC1A muscles. This
would be in line with previous published studies (as re-
ported above), would sustain diffuse and prolonged minia-
grin staining around muscle fibers of injected muscles
(and not elsewhere) and would justify the enhanced
expression of laminin-211 receptors (dystroglycan and
integrin α7β1) in MAB + mMAG injected muscles.
MABs + mMAG-treated dy2J mice showed a significant
reduction in the deterioration of motor performances with
the treadmill analysis as compared to those treated with
saline solution, whereas dy2J mice treated with MABs alone
did not behave better than those treated with saline.
Although MABs + mMAG-treated dy2J mice did not res-
cue motor performances towards normal values, this was
expected as we injected only few muscles of the posterior
limbs of dystrophic mice, and this therapy did not interfere
with the ongoing peripheral neuropathy. In fact, this would
simply constitute a proof-of-concept study on the feasibil-
ity of MABs + mMAG therapy for MDC1A. Nonetheless,
systemic administration of MABs + mMAG through the
arterial vascular system would constitute the gold standard
for future translational applications in MDC1A, as already
shown in other models [32, 36, 55], and recently in humans
(EudraCT no. 2011–000176–33; Giulio Cossu, manuscript
in preparation). In fact, MABs can cross the vessel wall
and distribute into the dystrophic muscles when delivered
intra-arterially. Unfortunately, repetitive intra-arterial injec-
tion of MABs in dy2J mice was not feasible for unexpected
arterial fragility. Moreover, efficacy of MABs + mMAG
treatment in our study was limited to dy2J mice, as more
severe model as dy3K die very early due to respiratory
failure and we had no chance to deliver engineered MABs
directly into the respiratory muscles.
Although MABs are not known to generate neural cell
types, as carrier cells, they may enter several tissues and
organs and may secrete mMAG in the peripheral nerves,
the other target organ of MDC1A. A progressive severe
dysmyelinating neuropathy is in fact associated to MDC1Ain humans and mouse models [17, 18, 49, 50], and it is
already known that genetic repletion of laminin chain α2 in
the skeletal muscles of mouse mutants does not completely
revert the clinical phenotype due to the progression of the
peripheral neuropathy [56]. Hence, we evaluated whether
MABs may engraft the peripheral nerves, secrete miniagrin,
and possibly ameliorate the peripheral neuropathy associ-
ated to MDC1A. Unfortunately, only few MABs entered
the endoneurium, while most were blocked in the perineur-
ium of peripheral nerves. This was not sufficient to produce
enough miniagrin to change the neuropathy outcome, as
demonstrated by pathological and neurophysiological eval-
uations. Part of this inefficient engraftment could also be
due to the presence of blood-nerve barrier. MABs
administration in mouse models with disrupted blood-
nerve barrier, as following nerve crush injury, showed
much higher MABs engraftment in the sciatic nerve
endoneurium (Stefano C. Previtali, unpublished data).
As other stem cell types have been shown to be better
carrier cells for peripheral nerve, i.e., hematopoietic stem
cells [29], future studies using combinatory cell therapies
such as hematopoietic stem cells to carry miniagrin in the
peripheral nerves and MABs + mMAG for the skeletal
muscle may constitute an ideal approach for multiorgan
disorders such as MDC1A.
Conclusions
The combination of cell plus gene therapy by MABs
engineered to produce and secrete MAG into the skeletal
muscles of MDC1A mutants showed significant efficacy to
ameliorate muscular dystrophy and motor performances of
dystrophic mice. This approach may speed translational
studies on the efficacy of miniagrin in human MDC1A, as
both MABs delivery and lentiviral transduced cells have
been already used in human clinical trials.
Additional files
Additional file 1: Figure S1. Quantification of TUNEL assay in sciatic nerves
section of dy2J mice untreated, treated with MABs, or with MABs + mMAG. (A)
TUNEL staining (green signal) in representative sections of the three treatment
conditions did not show significant differences (ANOVA, n= 3) as reported in
quantitative analysis (B). (TIFF 1.77 mb)
Additional file 2: Figure S2. Expression of laminin-411 and -511 in
treated and not-treated dy2J mice. (A) Western blot analysis of the tibialis
anterior muscle from wild type (Wt), dy2J mice untreated (saline) or dy2J
mice treated with MABs + mMAG or MABs alone stained with anti α4
laminin antibody, and α-actin as loading control. Quantification of Western
blot analysis is reported as an average of two independent experiments and
represented as the ratios α4 laminin/actin, assigning wild type as 1. Laminin
chain α4 is increased in muscle of dy2J mice, either untreated or treated
with MABs or MABs + mMAG, as compare to Wt control. (B) Cryosections of
the tibialis anterior muscle from Wt, dy2J mice untreated (saline solution) or
treated xwith MABs + mMAG stained with anti α5 laminin antibody. The
immunofluorescence shows that staining for α5 laminin is increased in dy2J
and dy2J treated with MABs + mMAG muscle as compared to Wt. Images
are acquired by confocal microscope, one single section with the same laser
intensity. DAPI staining identifies nuclei. (C) Cryosections of the tibialis anterior
Domi et al. Skeletal Muscle  (2015) 5:30 Page 16 of 17muscle from Wt, dy2J mice untreated (saline solution) or treated with MABs +
mMAG stained with anti γ1 laminin antibody. The immunofluorescence
shows that staining for γ1 laminin is reduced in muscle of dy2J and dy2J
mice treated with MABs + mMAG as compared to Wt. Images are acquired
by confocal microscope, one single section with the same laser intensity.
DAPI staining identifies nuclei. Scale bar = 100 μm. (TIFF 2.41 mb)
Additional file 3: Figure S3. Expression of integrin α6 in treated and
not-treated dy2J mice. Cryosections of the tibialis anterior muscle from Wt,
dy2J mice untreated (saline solution) or treated with MABs + mMAG stained
with anti α6 integrin antibody. The immunofluorescence shows positive
staining limited to the nerves and blood vessels in Wt skeletal muscle. In
dy2J mice, faint and dotted staining for α6 integrin in the skeletal muscle
was observed, as it was after mesoangioblast treatment (either MABs alone
or MABs + mMAG). DAPI staining identifies nuclei. Scale bar = 100 μm.
(TIFF 1.05 mb)
Additional file 4: Figure S4. Sciatic nerve of treated and not-treated
dy2J mice. (A) Semithin section of the sciatic nerve of not-treated (saline
solution) dy2J mouse 85-day-old showing bundles of unsorted axons and
hypomyelinated fibers. (B) Semithin section of the sciatic nerve of treated
(MABs + mMAG) dy2J mouse 85-day-old showing bundles of unsorted
axons and hypomyelinated fibers. (TIFF 1.59 mb)
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